LIFECARE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.1 NOK | +10.53% |
|
+16.67% | -52.91% |
| Jun. 06 | Life Sterilization Protocol Ready for the Production Line | CI |
| Jun. 04 | Norway’s Lifecare Seeks EU Patent for New Chemistry Composition | MT |
| Sales 2022 | 22.13 235.08 | Sales 2023 | 13.09 138.98 | Capitalization | 602M 6.39B |
|---|---|---|---|---|---|
| Net income 2022 | -17M -181M | Net income 2023 | -35M -372M | EV / Sales 2022 | 7,629,750 x |
| Net cash position 2022 | 43.28M 460M | Net cash position 2023 | 38.98M 414M | EV / Sales 2023 | 42,985,966 x |
| P/E ratio 2022 |
-12.1
x | P/E ratio 2023 |
-15.2
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 73.29% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +5.56% | ||
| Current month | -9.09% | ||
| 1 month | -30.40% | ||
| 3 months | -33.80% | ||
| 6 months | -45.24% | ||
| Current year | -57.40% |
1 week
1.75
2.11
1 month
1.693.20
Current year
1.696.32
1 year
1.426.32
3 years
1.156.32
5 years
0.589.00
10 years
0.589.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joacim Holter
CEO | Chief Executive Officer | 48 | 10-12-31 |
Andreas Pfützner
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 21-05-07 | |
Bo Petersson
BRD | Director/Board Member | - | 20-11-19 |
Lutz Heinemann
BRD | Director/Board Member | - | 20-11-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 2.1 | +10.53% | 856 846 |
| 24-06-12 | 1.9 | -0.11% | 605,314 |
| 24-06-11 | 1.902 | -1.14% | 59,413 |
| 24-06-10 | 1.924 | +1.26% | 620,038 |
| 24-06-07 | 1.9 | +5.56% | 913,209 |
Real-time Oslo Bors, June 13, 2024 at 03:08 am EDT
More quotes
Lifecare ASA is a Norway-based company that develops miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers. Lifecare's activities are concentrated on the development of sensor for use as a medical product, initially the sensor Sencell for continuous monitoring of glucose (blood sugar) for people with diabetes. The technology is suitable for detecting and measuring a wide range of molecules that can occur in the human body, based on variations in osmotic pressure.
Calendar
2024-08-27
- Q2 2024 Earnings Release
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -57.40% | 24.39M | |
| +48.54% | 56.61B | |
| +36.98% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| +12.97% | 26.44B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +28.18% | 12.51B | |
| +0.38% | 12.2B |
- Stock Market
- Equities
- LIFE Stock
